Safety of Recombinant Adeno-Associated Virus Type 2–RPE65 Vector Delivered by Ocular Subretinal InjectionSamuel G. Jacobson, William W. Hauswirth, Elizabeth A. M. Windsor et al.|Molecular Therapy|2006Cited by 223
Safety in Nonhuman Primates of Ocular AAV2- <i>RPE65</i> , a Candidate Treatment for Blindness in Leber Congenital AmaurosisSamuel G. Jacobson, William W. Hauswirth, Sanford L. Boye et al.|Human Gene Therapy|2006Cited by 147
Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogsRyan F. Boyd, Joshua T. Bartoe, Sanford L. Boye et al.|Gene Therapy|2016Cited by 37
Safety in Nonhuman Primates of Ocular AAV2-RPE65, a Candidate Treatment for Blindness in Leber Congenital AmaurosisSamuel G. Jacobson, William W. Hauswirth, Sanford L. Boye et al.|Human Gene Therapy|2006Cited by 12
881. Safety, Efficacy and Biodistribution of Recombinant AAV2-RPE65 Vector Delivered by Ocular Subretinal InjectionSamuel G. Jacobson, William W. Hauswirth, Terence R. Flotte et al.|Molecular Therapy|2006Cited by 0